Zacks Reiterates Neutral Rating for athenahealth (ATHN)
athenahealth (NASDAQ:ATHN)‘s stock had its “neutral” rating reaffirmed by Zacks in a research report issued to clients and investors on Friday, American Banking News reports. They currently have a $146.00 target price on the stock. Zacks‘ price target would suggest a potential upside of 4.98% from the stock’s previous close.
Zacks‘ analyst wrote, “Athenahealth’s 2013-fourth-quarter adjusted earnings of $0.43 per share significantly outpaced the Zacks Consensus earnings Estimate by $0.15. Revenues of $171.6 million also surpassed the Zacks Consensus Estimate of $169 million. The company has made rapid strides in capturing the EHR business of physician practices. Its takeover of Epocrates in early 2013 will allow it to grow its user base. However, the federal Stimulus is winding down. Larger competitors may benefit from the incumbency factor. Cloud computing may give rise to concerns about privacy and data security. As such, we maintain our Neutral recommendation on the stock and set a target of $146.00.”
In other athenahealth news, SVP Daniel Orenstein unloaded 1,000 shares of the stock on the open market in a transaction that occurred on Monday, February 3rd. The shares were sold at an average price of $146.73, for a total value of $146,730.00. Following the completion of the sale, the senior vice president now directly owns 31,262 shares in the company, valued at approximately $4,587,073. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.
Other equities research analysts have also recently issued reports about the stock. Analysts at Sterne Agee raised their price target on shares of athenahealth from $179.00 to $192.00 in a research note to investors on Friday. Separately, analysts at Raymond James upgraded shares of athenahealth from an “outperform” rating to a “strong-buy” rating in a research note to investors on Friday, December 13th. They now have a $150.00 price target on the stock. Finally, analysts at Leerink Swann upgraded shares of athenahealth from a “market perform” rating to an “outperform” rating in a research note to investors on Friday, December 13th. They now have a $150.00 price target on the stock. Three equities research analysts have rated the stock with a sell rating, eight have issued a hold rating, seven have issued a buy rating and one has given a strong buy rating to the stock. The company currently has an average rating of “Hold” and an average target price of $138.93.
athenahealth (NASDAQ:ATHN) traded up 25.64% during mid-day trading on Friday, hitting $174.74. 2,837,063 shares of the company’s stock traded hands. athenahealth has a 52-week low of $82.01 and a 52-week high of $148.55. The stock’s 50-day moving average is $136.7 and its 200-day moving average is $123.8. The company’s market cap is $6.495 billion.
athenahealth (NASDAQ:ATHN) last released its earnings data on Thursday, February 6th. The company reported $0.57 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.45 by $0.12. The company had revenue of $171.60 million for the quarter, compared to the consensus estimate of $168.39 million. During the same quarter in the prior year, the company posted $0.29 earnings per share. The company’s quarterly revenue was up 47.5% on a year-over-year basis. Analysts expect that athenahealth will post $1.04 EPS for the current fiscal year.
athenahealth, Inc (NASDAQ:ATHN), is a business services company, which provides ongoing billing, clinical-related, and other related services to its customers.
To view Zacks’ full report, visit www.zacks.com
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.